This study evaluated the effects of aquatic physical therapy on improvement in fatigue symptoms and quality of life (QoL) in patients with breast cancer (BC). The data showed that aquatic physical therapy reduced fatigue symptoms and improved the QoL in women with BC.

This study evaluated the effectiveness and safety of the Pfizer/BioNTech BNT162b2 COVID-19 vaccine in patients with breast and gynecological cancer. The data showed that most patients with breast and gynecological cancer developed antibodies after the second dose of the vaccine. However, the authors suggested that for non-responders or weak responders, additional immunization booster seems to be required, along with proactive planning in the vaccination schedule, with vaccine administration spaced out over time with respect to chemotherapy.

The study evaluated the effectiveness of physical exercise (PE) programs in breast cancer (BC) survivors on health-related quality of life (HRQoL), physical fitness, and body composition. The study concluded that PE programs do have a positive impact on BC survivors’ HRQoL, physical fitness, and body composition.

The study evaluated the effectiveness of vaginal laser therapy (VL) and hyaluronic acid suppositories (HAS) in women with urogenital atrophy after having breast cancer (BC) treatment. The data found that both VA therapy and HAS were equally effective in treating urogenital atrophy in these patients.

The study evaluated the effectiveness of aquatic therapeutic exercise in breast cancer survivors for improving symptoms and quality of life. The study found that aquatic therapeutic exercise effectively improved fatigue, pain, and quality of life in these patients.

This study evaluated the impact of immune checkpoint inhibitors (ICIs) on COVID-19 outcomes in patients with cancer. The data showed that the use of ICI treatment before COVID-19 infection does not affect the disease severity or survival outcomes. This study supports the continued use of ICIs in cancer patients during the pandemic.

This study compared the effectiveness and safety of immune checkpoint inhibitors (ICI) plus chemotherapy versus chemotherapy alone for the treatment of patients with triple-negative breast cancer (TNBC). The data showed that ICI plus chemotherapy was more effective than chemotherapy alone and was associated with a higher rate of side effects in patients with TNBC.

This study evaluated the long-term benefits and risks of trastuzumab (Herceptin) plus chemotherapy in patients with early-stage HER2-positive (+) breast cancer (BC). The data showed that trastuzumab added to chemotherapy reduced the risk of BC recurrence and death for these patients.

This study investigated the side effect profiles of different PD-1/PD-L1 inhibitor-based combination therapies. The data showed that PD-1/PD-L1 inhibitors in combination with chemotherapy were associated with a higher risk of treatment-related side effects than with targeted therapy or immunotherapy combinations.

This study is aimed to evaluate the risk of infection for patients who are treated with immune checkpoint inhibitors (ICI) for solid tumors. The study concluded that in frail patients, ICI therapy alone is safer compared to chemotherapy (CT).